Vascular smooth muscle Jak2 mediates angiotensin II-induced hypertension via increased levels of reactive oxygen species

Cardiovascular Research

Volumn 91, Issue 1, 2011, Pages 171-179

  Kirabo, Annet ^a   Kearns, Patrick N ^a   Jarajapu, Yagna P ^a   Sasser, Jennifer M ^a   Oh, Suk Paul ^a   Grant, Maria B ^a   Kasahara, Hideko ^a   Cardounel, Arturo J ^a   Baylis, Chris ^a   Wagner, Kay Uwe ^b,c   Sayeski, Peter P ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Angiotensin II; Hypertension; Jak2 tyrosine kinase; Vascular smooth muscle cell

Indexed keywords

ANGIOTENSIN II; CALCIUM ION; CRE RECOMBINASE; JANUS KINASE 2; REACTIVE OXYGEN METABOLITE; RHO KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; HYPERTENSION; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; VASCULAR RING; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; AORTA; BLOOD PRESSURE; CALCIUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HYDROGEN PEROXIDE; HYPERTENSION; JANUS KINASE 2; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RHO-ASSOCIATED KINASES; TIME FACTORS; UP-REGULATION; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 79958833775     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr059     Document Type: Article

References (52)

1. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-1762. (Pubitemid 28269185)
2. Bhat GJ, Thekkumkara TJ, Thomas WG, Conrad KM, Baker KM. Angiotensin II stimulates sis-inducing factor-like DNA binding activity. Evidence that the AT1A receptor activates transcription factor-Stat91 and/or a related protein. J Biol Chem 1994;269: 31443-31449.
3. Bhat GJ, Thekkumkara TJ, Thomas WG, Conrad KM, Baker KM. Activation of the STAT pathway by angiotensin II in T3CHO/AT1A cells. Cross-talk between angiotensin II and interleukin-6 nuclear signaling. J Biol Chem 1995;270:19059-19065.
4. Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P et al. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 1995;375: 247-250.
5. Marrero MB, Schieffer B, Li B, Sun J, Harp JB, Ling BN. Role of Janus kinase/signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II- and platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem 1997;272:24684-24690. (Pubitemid 27418687)
6. Ali MS, Sayeski PP, Dirksen LB, Hayzer DJ, Marrero MB, Bernstein KE. Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor. J Biol Chem 1997;272:23382-23388. (Pubitemid 27392480)
7. McWhinney CD, Hunt RA, Conrad KM, Dostal DE, Baker KM. The type I angiotensin II receptor couples to Stat1 and Stat3 activation through Jak2 kinase in neonatal rat cardiac myocytes. J Mol Cell Cardiol 1997;29:2513-2524. (Pubitemid 27404443)
8. Dostal DE, Hunt RA, Kule CE, Bhat GJ, Karoor V, McWhinney CD et al. Molecular mechanisms of angiotensin II in modulating cardiac function: intracardiac effects and signal transduction pathways. J Mol Cell Cardiol 1997;29:2893-2902. (Pubitemid 27510756)
9. Pan J, Fukuda K, Kodama H, Makino S, Takahashi T, Sano M et al. Role of angiotensin II in activation of the JAK/STAT pathway induced by acute pressure overload in the rat heart. Circ Res 1997;81:611-617. (Pubitemid 27432749)
10. Kodama H, Fukuda K, Pan J, Makino S, Sano M, Takahashi T et al. Biphasic activation of the JAK/STAT pathway by angiotensin II in rat cardiomyocytes. Circ Res 1998;82: 244-250. (Pubitemid 28080107)
11. Pan J, Fukuda K, Saito M, Matsuzaki J, Kodama H, Sano M et al. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 1999;84:1127-1136. (Pubitemid 29244774)
12. Seki Y, Kai H, Shibata R, Nagata T, Yasukawa H, Yoshimura A et al. Role of the JAK/ STAT pathway in rat carotid artery remodeling after vascular injury. Circ Res 2000;87: 12-18. (Pubitemid 30456929)
13. Guilluy C, Bregeon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, Loufrani L, Henrion D et al. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med 2010;16:183-190.
14. Kleinberger-Doron N, Shelah N, Capone R, Gazit A, Levitzki A. Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase. Exp Cell Res 1998;241:340-351. (Pubitemid 28366560)
15. Oda Y, Renaux B, Bjorge J, Saifeddine M, Fujita DJ, Hollenberg MD. cSrc is a major cytosolic tyrosine kinase in vascular tissue. Can J Physiol Pharmacol 1999;77:606-617.
16. Levitzki A. Tyrphostins-potential antiproliferative agents and novel molecular tools. Biochem Pharmacol 1990;40:913-918. (Pubitemid 20259692)
17. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res 2006;71: 247-258.
18. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells- implications in cardiovascular disease. Braz J Med Biol Res 2004;37:1263-1273. (Pubitemid 39172561)
19. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003;42:1075-1081. (Pubitemid 37549058)
20. Ushio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K et al. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 1999;274:22699- 22704.
21. Yan C, Kim D, Aizawa T, Berk BC. Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Arterioscler Thromb Vasc Biol 2003;23: 26-36. (Pubitemid 36091622)
22. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000;20:2175-2183.
23. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501. (Pubitemid 30165039)
24. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-1923.
25. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998;32:488-495. (Pubitemid 28429138)
26. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996;271:23317-23321. (Pubitemid 26314775)
27. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148. (Pubitemid 24176909)
28. Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Mugge A et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 1999;44:215-222. (Pubitemid 29431699)
29. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-C97. (Pubitemid 46127306)
30. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-456. (Pubitemid 16097810)
31. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-H827.
32. Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-1052. (Pubitemid 32304002)
33. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997;95:588-593. (Pubitemid 27063033)
34. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol 1997;20:II-17.
35. Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K et al. Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem 2006; 281:18177-18183. (Pubitemid 44035617)
36. Mao X, Fujiwara Y, Orkin SH. Improved reporter strain for monitoring Cre recombinase-mediated DNA excisions in mice. Proc Natl Acad Sci USA 1999;96: 5037-5042. (Pubitemid 29214531)
37. Falkenhahn M, Gohlke P, Paul M, Stoll M, Unger T. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects. J Cardiovasc Pharmacol 1994; 24(Suppl. 2):S6-S13. (Pubitemid 24369879)
38. Tham DM, Martin-McNulty B,Wang YX, Da Cunha V, Wilson DW, Athanassious CN et al. Angiotensin II injures the arterial wall causing increased aortic stiffening in apolipoprotein E-deficient mice. Am J Physiol Regul Integr Comp Physiol 2002;283: R1442-R1449. (Pubitemid 35340658)
39. Muthalif MM, Parmentier JH, Benter IF, Karzoun N, Ahmed A, Khandekar Z et al. Ras/ mitogen-activated protein kinase mediates norepinephrine-induced phospholipase D activation in rabbit aortic smooth muscle cells by a phosphorylation-dependent mechanism. J Pharmacol Exp Ther 2000;293:268-274. (Pubitemid 30180948)
40. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH et al. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 2000;101:2030-2033. (Pubitemid 30233164)
41. Begum N, Duddy N, Sandu O, Reinzie J, Ragolia L. Regulation of myosin-bound protein phosphatase by insulin in vascular smooth muscle cells: evaluation of the role of Rho kinase and phosphatidylinositol-3-kinase-dependent signaling pathways. Mol Endocrinol 2000;14:1365-1376.
42. Jin L, Ying Z, Webb RC. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am J Physiol Heart Circ Physiol 2004;287:H1495-H1500. (Pubitemid 39313251)
43. Jernigan NL, Walker BR, Resta TC. Reactive oxygen species mediate RhoA/Rho kinase-induced Ca2+ sensitization in pulmonary vascular smooth muscle following chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 2008;295:L515-L529.
44. Boos CJ, Dawes M. ACE cardiovascular protection: EUROPA versus HOPE. Cardiovasc Drugs Ther 2004;18:179-180. (Pubitemid 38918950)
45. Huang F, Thompson JC, Wilson PG, Aung HH, Rutledge JC, Tannock LR. Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J Lipid Res 2008;49:521-530.
46. Henriques TA, Huang J, D'Souza SS, Daugherty A, Cassis LA. Orchidectomy, but not ovariectomy, regulates angiotensin II-induced vascular diseases in apolipoprotein Edeficient mice. Endocrinology 2004;145:3866-3872. (Pubitemid 39037575)
47. Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B, Lodder RA. Mechanisms contributing to angiotensin II regulation of body weight. Am J Physiol 1998;274:E867-E876.
48. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000;105: 1605-1612. (Pubitemid 30390311)
49. Skinner S, Bouhnik J, Huang H, Gonzalez MF, Ménard J, Corvol P. Plasma angiotensin in binephrectomised mice. Clin Exp Hypertens 1995;17:847-860.
50. Shaw S, Wang X, Redd H, Alexander GD, Isales CM, Marrero MB. High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway. J Biol Chem 2003;278:30634-30641. (Pubitemid 36994568)
51. Delhommeau F, Pisani DF, James C, Casadevall N, Constantinescu S, Vainchenker W. Oncogenic mechanisms in myeloproliferative disorders. Cell Mol Life Sci 2006;63: 2939-2953. (Pubitemid 46072300)
52. Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program 2009;1:636-642.